Circulating immune response proteins predict the outcome following disease progression of osimertinib treated epidermal growth factor receptor-positive non-small cell lung cancer patients

BACKGROUND: Lung cancer patients with sensitizing epidermal growth factor receptor (EGFR) mutations treated with osimertinib will eventually develop progressive disease (PD). The survival following PD varies greatly between patients, and no effective treatment strategy has been established. Furtherm...

Descripción completa

Detalles Bibliográficos
Autores principales: Maansson, Christoffer T., Helstrup, Sofie, Ebert, Eva B. F., Meldgaard, Peter, Sorensen, Boe S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9903085/
https://www.ncbi.nlm.nih.gov/pubmed/36762069
http://dx.doi.org/10.21037/tlcr-22-577

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9903085/
https://www.ncbi.nlm.nih.gov/pubmed/36762069
http://dx.doi.org/10.21037/tlcr-22-577

Ejemplares similares